Notice2024-04166
Timothy Baxter; Final Order Announcing Termination Date of Debarment
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
February 29, 2024
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA or Agency) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) announcing that the debarment of Timothy Baxter will terminate on October 26, 2025.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 41 (Thursday, February 29, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 41 (Thursday, February 29, 2024)]
[Notices]
[Page 14861]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-04166]
[[Page 14861]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2021-N-0028]
Timothy Baxter; Final Order Announcing Termination Date of
Debarment
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is issuing an
order under the Federal Food, Drug, and Cosmetic Act (FD&C Act)
announcing that the debarment of Timothy Baxter will terminate on
October 26, 2025.
DATES: This order is applicable February 29, 2024.
ADDRESSES: Submit comments electronically at <a href="https://www.regulations.gov">https://www.regulations.gov</a>. Written comments may be submitted to the Dockets
Management Staff, Food and Drug Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852, 240-402-7500.
FOR FURTHER INFORMATION CONTACT: Jaime Espinosa, Division of Compliance
and Enforcement, Office of Policy, Compliance, and Enforcement, Office
of Regulatory Affairs, Food and Drug Administration, at 240-402-8743 or
<a href="/cdn-cgi/l/email-protection#ef8b8a8d8e9d828a819b9caf898b8ec187879cc1888099"><span class="__cf_email__" data-cfemail="1c78797e7d6e717972686f5c7a787d3274746f327b736a">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: In a Federal Register notice dated February
27, 2023 (88 FR 12369), FDA issued an order debarring Dr. Timothy
Baxter pursuant to section 306(b)(2)(B)(i)(I) of the FD&C Act (21
U.S.C. 335a(b)(2)(B)(i)(I)) for a period of 5 years from providing
services in any capacity to a person with an approved or pending drug
product application under section 505, 512, or 802 of the FD&C Act (21
U.S.C. 355, 360b, or 382), or under section 351 of the Public Health
Service Act (42 U.S.C. 262). Through mutual agreement of the parties,
the Assistant Commissioner, Office of Human and Animal Food Operations,
under section 306(d) of the FD&C Act and under authority delegated to
the Assistant Commissioner, issues this order announcing that Dr.
Baxter's period of debarment will now terminate on October 26, 2025.
Dated: February 23, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024-04166 Filed 2-28-24; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on February 29, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.